Optimized long-read sequencing constructs megabase-scale genome assemblies from complex soil samples.

A screen for protein degraders discovers hits by imaging cell survival.

LexicMap uses a fixed set of probes to efficiently query gene sequences for fast and low-memory alignment.

Antibody–bottlebrush conjugates expand the options for drug cargos compared to antibody–drug conjugates.

A resource of human RNA-protein associations is produced using a sequencing-based method.

Append editing of ADP-ribosyl to thymine is used for precise modifications in bacteria and eukaryotes.

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Enlaza Therapeutics is developing protein-based therapeutics that bind irreversibly to their target.

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. City Therapeutics is using very small cityRNAs to broaden the range of siRNA therapeutics.

The COP16 decision established a multilateral mechanism for digital sequence information (DSI) benefit-sharing. This Comment brings together insights from academia and commercial DSI researchers to assess what has been accomplished so far, identify remaining challenges and describe elements under discussion to support collective goals.